News
The trial judged the tolerability, safety and efficacy of atogepant, at 60 mg once daily, compared to the highest-tolerated ...
11h
Zacks.com on MSNLLY vs. ABBV: Which Pharma Powerhouse is the Better Bet?Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Antibody-drug conjugates, or ADCs, are still holding on to their spot as one of the hottest areas in cancer care—and AbbVie, ...
The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.64 per share.
Now is a great time for income and value investors, especially in energy and pharma, with dividends and upside potential.
Johnson & Johnson (NYSE:JNJ) said that an advisory committee of the EU drug regulator, the European Medicines Agency (EMA), ...
EULAR now recommends moving directly to biologic or targeted synthetic disease-modifying antirheumatic drugs if the initial ...
With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...
Protagonist Therapeutics' partners ought to secure two approvals for blockbuster drugs within the next year. Click here to ...
The shipments have vaulted Ireland, a country of only five million people, into the second-largest goods-trade imbalance with the U.S., trailing only China.
In the US, patients diagnosed with noninfectious uveitis (NIU) are higher in number than infectious uveitis (IU). In 2022, ...
In CAR T-cell therapy for diffuse large B-cell lymphoma, distinct archetypes could guide personalized treatment decisions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results